Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.94 USD | +6.41% | +37.06% | +75.16% |
17/04 | North American Morning Briefing : Stock Futures -2- | DJ |
16/04 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 16.48M 1.37B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.75B | Net income 2025 * | -36M -3B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-17.5
x | P/E ratio 2025 * |
-16.4
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | +6.41% | ||
1 week | +37.06% | ||
Current month | -26.71% | ||
1 month | -26.71% | ||
3 months | +258.20% | ||
6 months | -33.45% | ||
Current year | +75.16% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 01/20/01 |
Director of Finance/CFO | 40 | 01/18/01 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 10/21/10 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 12/20/12 |
Garry Neil
CEO | Chief Executive Officer | 70 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 15.94 | +6.41% | 78,226 |
25/24/25 | 14.98 | +5.49% | 160,992 |
24/24/24 | 14.2 | +9.23% | 37,075 |
23/24/23 | 13 | +6.47% | 73,477 |
22/24/22 | 12.21 | +4.99% | 83,471 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.16% | 16.48M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AVTX Stock